GlassScriptPhysician profile
Vincent Stephan Izzi
NPI 1467832683
$13,176.55
in general payments reported to CMS, 2019-2025
53 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $1,226 · 2021: $2,521 · 2022: $1,950 · 2023: $1,869 · 2024: $2,235 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,058.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,711.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,665.78 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,406.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $756.97 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $632.36 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $522.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $512.58 | 2020-2025 | Verquvo, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.89 | 2019-2025 | Jardiance |
| Allergan, INC. | $482.25 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $466.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $438.46 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $347.67 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $308.62 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $300.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $271.02 | 2024-2025 | Hetlioz, Fanapt |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Izzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.